Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 2 NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Diabetes Mellitus, Type 1 1

Interventions

Specimen Handling 180 Cyclophosphamide 161 Magnetic Resonance Spectroscopy 153 Biopsy 128 Radiotherapy 109 Cisplatin 109 Bevacizumab 107 Carboplatin 101 Doxorubicin 96 Paclitaxel 94 Etoposide 87 Filgrastim 81 aldesleukin 78 Gemcitabine 73 Vincristine 72 Fluorouracil 72 Leucovorin 62 fludarabine phosphate 58 Docetaxel 58 Bortezomib 54 Sorafenib 53 Cytarabine 51 Methotrexate 50 Taxes 49 Immunoglobulin G 49 Disulfides 49 Rituximab 48 Oxaliplatin 48 sargramostim 47 Prednisone 47

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × NIH × golimumab × Clear all

NCT04729296 2021-12-02

Anti-TNFα to Delay or Prevent Progression to Stage 3 T1D

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Phase 2 Withdrawn

Diabetes Mellitus, Type 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡